TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion

Trial Profile

TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Triamcinolone (Primary) ; Aflibercept
  • Indications Retinal oedema; Retinal vein occlusion
  • Focus Therapeutic Use
  • Acronyms TANZANITE
  • Sponsors Clearside Biomedical
  • Most Recent Events

    • 09 Nov 2016 According to a Clearside Biomedical media release, data from the study has been presented During the 2016 Retina Sub-Specialty Day at the American Academy of Ophthalmology annual meeting in October.
    • 10 Oct 2016 According to a Clearside Biomedical media release, data from the study will be presented at the Retina Sub-Specialty Day Meeting at the 2016 American Academy of Ophthalmology (AAO) Meeting.
    • 26 Jul 2016 According to a Clearside Biomedical media release, the company expects to have an end-of-phase II meeting with the FDA in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top